section name header

Pronunciation

am-FET-a-meen

Classifications

Therapeutic Classification: central nervous system stimulants

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed in body tissues, with high concentrations in the brain and CSF.

Metabolism/Excretion: Some metabolism by the liver. Urinary excretion is pH-dependent. Alkaline urine promotes reabsorption and prolongs action.

Half-life: 10–15 hr.

Time/Action Profile

(CNS stimulation)

ROUTEONSETPEAKDURATION
PO1–2 hrunknown4–10 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypertension, palpitations, tachycardia, cardiomyopathy ( with prolonged use, high doses), hypotension, peripheral vasculopathy, SUDDEN DEATH.

Derm: urticaria.

Endo: growth inhibition (with long term use in children).

GI: anorexia, constipation, diarrhea, cramps, dry mouth, intestinal ischemia, metallic taste, nausea, vomiting.

GU: erectile dysfunction, libido.

Neuro: hyperactivity, insomnia, restlessness, tremor, dizziness, headache, irritability, tics, Tourette's syndrome.
Misc: fever, (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS , physical dependence, psychological dependence, tolerance.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

Attention-Deficit/Hyperactivity Disorder

Narcolepsy

Obesity

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Adzenys ER, Adzenys-XR ODT, Dyanavel XR, Evekeo

Contr. Subst. Schedule

Schedule II (C-II)